TrademarkDir
BIOCLATE
DEAD

Serial Number

74395612

Owner

ARMOUR PHARMACEUTICAL COMPANY

First Use Date

Dec 30, 1993

Filing Date

May 25, 1993

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

BIOCLATE Trademark

Serial Number: 74395612 • Registration: 1914063

BIOCLATE is a trademark filed by ARMOUR PHARMACEUTICAL COMPANY on May 25, 1993. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ARMOUR PHARMACEUTICAL COMPANY (166 trademarks)

PRUDENTIAL PLAZA
CHICAGO, IL

Entity Type: 03

AVENTIS BEHRING L.L.C. (14 trademarks)

1020 First Avenue
King of Prussia, PA 19406

Entity Type: 16

Trademark Details

Filing Date

May 25, 1993

Registration Date

August 22, 1995

First Use Anywhere

December 30, 1993

First Use in Commerce

December 30, 1993

Published for Opposition

December 28, 1993

Cancellation Date

May 27, 2006

Goods & Services

pharmaceutical preparation for the treatment of blood disorders

Filing History

CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
May 27, 2006 CAEX
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Aug 25, 2001 C15A
REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
Aug 2, 2001 815F
REGISTERED-PRINCIPAL REGISTER
Aug 22, 1995 R.PR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 10, 1995 CNPR
ASSIGNED TO EXAMINER
May 9, 1995 DOCK
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 17, 1995 CRFA
NON-FINAL ACTION MAILED
Oct 17, 1994 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Oct 7, 1994 SUPC
USE AMENDMENT FILED
Sep 9, 1994 IUAF
NOA MAILED - SOU REQUIRED FROM APPLICANT
Mar 22, 1994 NOAM
PUBLISHED FOR OPPOSITION
Dec 28, 1993 PUBO
NOTICE OF PUBLICATION
Nov 26, 1993 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 22, 1993 CNSA
ASSIGNED TO EXAMINER
Oct 22, 1993 DOCK

Related Trademarks

More from this Owner

ZEMAIRA

ZEMAIRA

ZEMAIRA

ZEMAIRA

ZEMAIRA

ZEMAIRA

PACT PATIENT ACCESS TO CHRONIC THERAPIES logo

PACT PATIENT ACCESS TO CHRONIC THERAPIES

PACT PATIENT ACCESS TO CHRONIC THERAPIES logo

PACT PATIENT ACCESS TO CHRONIC THERAPIES

SELASTIN

SELASTIN